Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triumeq phase 3 trial in amyotrophic lateral sclerosis
NL-OMON54227Phase 3Recruiting
- Sponsor
- TRICALS
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Triumeq with Placebo (2 arms). Primary endpoint: Overall survival. Started May 2023; status: recruiting.
02
Drugs
abacavir
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON54227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54227.